Community protocol
Third-partySemax 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 0.5 mg
- 03Syringe units
- 5 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 5
Semax
A stabilised fragment of ACTH with the hormonal activity removed, registered in Russia for stroke and cognitive indications. Evidence is almost entirely Russian.
Overview
ACTH is the hormone that drives cortisol release, but a short section of it turns out to have effects on the brain that have nothing to do with cortisol. Semax is that section, with a stabilising tail added. It does not raise cortisol. The reported effects are on attention, memory and recovery after ischaemic injury, with a proposed mechanism running through increased BDNF expression in the hippocampus.
Met-Glu-His-Phe-Pro-Gly-Pro, the ACTH(4-10) heptapeptide extended with Pro-Gly-Pro for enzymatic stability, devoid of corticotropic activity. Reported to rapidly upregulate BDNF and TrkB expression in rat hippocampus, modulate dopaminergic and serotonergic transmission, and produce neuroprotective effects in middle cerebral artery occlusion models. Registered in Russia for ischaemic stroke, transient ischaemic attack, optic nerve atrophy and cognitive indications. Clinical evidence comprises Russian trials of moderate size; the compound has no Western regulatory history and no independent international replication.
Research areas
Ischaemic strokeCognitive performanceBDNF signallingOptic neuropathy
Community-specified data
Community dosage information
Community protocol
Third-partySemax 15mg + Selank 15mg
- 01Reconstitution solution
- 1.5 mL
- 02Dose
- 0.5 mg
- 03Syringe units
- 5 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1.5 mL
- 07Bottle size
- 30 mg
- 08Bottles needed
- 2
Community protocol
Third-partyNA Semax Nasal Spray
- 01Reconstitution solution
- Not specified
- 02Dose
- 0.4 mg
- 03Syringe units
- 3 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- Not specified
- 07Bottle size
- 20 mg
- 08Bottles needed
- Not specified
Source note: 3 sprays per dose. No reconstitution needed.
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 1% intranasal solution, high-dose regimen in acute ischaemic stroke over 10 days | Russian stroke treatment protocol |
| 0.1% intranasal solution for cognitive and asthenic indications over 14 days | Russian registered labelling |
Trial status
Russian clinical trials in ischaemic stroke and cognitive disorders. No Western registered programme.
Reported safety signals
- Nasal irritation is the commonly reported local effect.
- Long-term safety has not been established in any controlled study.
- Despite being an ACTH fragment, it does not stimulate cortisol — but this has been verified only in the originating literature.
- Material sold outside Russia is unregulated with unverified identity and concentration.
Common questions
Does Semax raise cortisol, given it comes from ACTH?
No. The 4-10 fragment lacks the region required to activate the melanocortin-2 receptor that drives cortisol release. That separation of behavioural effects from hormonal effects is the whole reason the fragment was pursued.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →